AbbVie’s strength has long been tied to the performance of megablockbuster Humira, which is facing an existential threat as U.S. copycats creep closer. Despite a “more aggressive” than expected biosimilar challenge abroad, AbbVie believes its defense strategy—and lessons learned—will help it weather the storm. In an earnings call with analysts Friday, AbbVie CEO Rick Gonzalez touted the drugmaker’s… Read More: AbbVie touts Humira defense strategy abroad as a positive sign… »